Press Release, Lund December 18, 2019 Hamlet Pharma is on track with its plans to engage in a clinical trial of Alpha1H for the treatment…
Read More
BioWorld. November 6, 2019 By Cormac Sheridan – DUBLIN – Hamlet Pharma AB is about to embark on the next phase in the clinical development…
Aktieägarna i Hamlet Pharma AB, 556568-8958, kallas härmed till årsstämma torsdagen den 21 november 2019 kl. 17.30 i Gamla Börssalen, Malmö Börshus med adress Skeppsbron…
At the end of July 2019, Hamlet Pharma announced the successful completion of the Phase I/II bladder cancer study. We now provide more detailed information…
Hamlet Pharma is proud to announce the successful outcome of the Phase I/II trial, aimed at studying the safety and efficacy of Alpha1H in patients…
The ongoing phase I/II study with 40 patients is due to complete in May/June 2019. The last study patient is expected to undergo scheduled surgery…
The phase I/II study in patients with bladder cancer addresses the safety of our drug candidate Alpha1H and measures biomarkers of efficacy. The protocol is…
HAMLET Pharma AB is pleased to announce that we have received a notification from the European Patent Office (EPO) regarding a patent application with claims…
Hamlet Pharma takes a further step towards the start of the clinical study in patients with bladder cancer. The company has received ethical approval of…
Hamlet Pharma announces that the production of the Alpha1H peptide has been successful and that the peptide is ready for delivery. The peptide meets the…
On April 11th, the British newspaper The Daily Telegraph published a feature article about HAMLET and the founder of Hamlet Pharma Professor Catharina Svanborg, following…